Drugs / Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01942265 | Sep 2013 → Jan 2015 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01942265 ↗ |
| Modality | Vaccine | “monovalent influenza A/H7N9 virus vaccine” NCT01942265 ↗ |
| Route | Intramuscular | “delivered intramuscularly approximately 21 days apart” NCT01942265 ↗ |